FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause

"Hot flashes as a result of menopause can be a serious physical burden on women and impact their quality of life," said Janet Maynard, M.D., M.H.S., direct...

May 15, 2023 | Monday | News
MediciNova granted new patent for MN-166 (ibudilast) in Europe for microorganism infection

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than February 2039. The allowed claims cover MN...

May 15, 2023 | Monday | News
Veeva Partners with Sanofi to Transform its Quality System

Veeva Systems (NYSE: VEEV) today announced that Sanofi is implementing Veeva Vault QMS and Veeva Vault QualityDocs to modernize quality management across t...

May 11, 2023 | Thursday | News
China NMPA Approves TYVYT® Combo for EGFR-mutated NSCLC Patients Who Progressed After EGFR-TKI Therapy

This is the seventh NMPA-approved indication of TYVYT® (sintilimab injection). The first six indications of TYVYT® (sintilimab injection) are inclu...

May 10, 2023 | Wednesday | News
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA)...

May 08, 2023 | Monday | News
Junshi Biosciences and Dr. Reddy's Partner to Develop Toripalimab in 21 Countries.

“We are thrilled to have established a partnership with Dr. Reddy’s while toripalimab’s global commercial network has been steadily expan...

May 08, 2023 | Monday | News
Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

Nicola Thompson, CEO of Amphista, said, "We are absolutely delighted with the progress and success of our collaboration with BMS. Our ability to deliver ou...

May 05, 2023 | Friday | News
Moderna and Merck's Neoantigen Therapy, mRNA-4157, Shows Superior Survival in High-Risk Stage III/IV Melanoma Patients Compared to KEYTRUDA

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients...

May 04, 2023 | Thursday | News
Akorn Recalls Expired Human and Animal Drugs Nationwide Due to Shutdown

Akorn Operating Company LLC has filed Chapter 7 bankruptcy on February 23, 2023. In connection with that filing, the company has ceased and shutdow...

May 04, 2023 | Thursday | Regulatory
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health

PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce the establishment of a 50:50 joint venture, "Cortexa", with Austr...

May 02, 2023 | Tuesday | News
Aurora Expands Medical Cannabis Portfolio in Germany

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and a leading manufacturer a...

May 01, 2023 | Monday | News
Aquavit Receives FDA Clearance for Two INDs to Initiate Clinical Trials With Its Botulinum Toxin

Aquavit will begin its Phase II/Phase III trials for DTX-023 (aqubotulinumtoxinA) and DTX-024 (aqubotulinumtoxinA with intradermal microinjector) under the...

May 01, 2023 | Monday | News
Pfizer and Astellas' XTANDI® Combo Proves Effective in Reducing Prostate Cancer Metastasis Risk by 58%: Phase 3 EMBARK Trial Results Revealed

Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting Res...

May 01, 2023 | Monday | News
Janssen Reports First Results of TAR-200 and Cetrelimab Study in Non-Muscle-Invasive Bladder Cancer

Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need T...

May 01, 2023 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close